2018-03-05 - OBSERVABLE Meeting

1

Welcome & apologies

Daniel Karlsson

2

Conflicts of interest

Daniel Karlsson

• None stated
  
  

3

Previous minutes

Daniel Karlsson

4

LOINC collaboration

Farzaneh Ashrafi

Daniel Karlsson

Rob Hausam

+all

• Likelihood

  • Two distinct cases were identified:

    1. Specifying certainty (or uncertainty) about the result of an observation. Examples: Fetal sex, Trisomy 21 present by "Dosage of chromosome specific cf DNA" method.

    2. Prediction of a possible future event based on varying amount of information about the patient, from population-only based assessment (i.e. prevalence) to assessment based on several variables. Examples include 1p36 deletion risk based on population risk, Trisomy 21 risk based on maternal age, to the CHADS-VASC instrument.

Example values:

5

Susceptibility

Farzaneh Ashrafi

• Mapping of LOINC component for Susceptibility LOINC terms

  • Two alternatives for representing LOINC component / SNOMED Towards:

    1. Use substances: have to add combined substances for combined antibiotics, e.g. Amoxicillin+Clavulanic acid. Cannot represent strenghts. Cannot represent only vs. contains semantics(?).

    2. Use products: Depending on drug project, may represent only/contains, can represent strength, can represent combinations. This was the alternative proposed by the project group.

  • Strength-specified antibiotics are used in some susceptibility tests, particularly for mycobacteria, and the model would need to represent strengths somehow.

6

Face-to-face

Daniel Karlsson

• LOINC - SNOMED issues (1h)

• Other future areas will be explored, e.g. device observables, diet observables.

7

Next meeting

Daniel Karlsson

• Next meeting is on the 2018-03-19 20.00 UTC

8

AOB

Daniel Karlsson